VolitionRX

VNRX

Market cap $38.2M

HENDERSON, Nev. , Nov. 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the first sale of its Nu.Q® Cancer assays to one of Europe's leading cancer centers, the Hospices Civils de Lyon, in Lyon, France.

VolitionRx Limited ( VNRX ) Q3 2025 Earnings Call November 14, 2025 8:30 AM EST Company Participants Louise Batchelor Day - Group Chief Marketing & Communications Officer Cameron Reynolds - Founder, CEO, President & Director Jacob Micallef - Chief Scientific Officer Terig Hughes - CFO & Treasurer Conference Call Participants Justin Walsh - JonesTrading Institutional Services, LLC, Research Division Yi Chen - H.C. Wainwright & Co, LLC, Research Division Steven Ralston - Zacks Investment Research, Inc. Bruce Jackson - The Benchmark Company, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and thank you for standing by.

Conference call to discuss financial and operational results scheduled for Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nevada , Nov. 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter ended September 30, 2025.

Conference call to take place on Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

HENDERSON, Nev. , Oct. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), and its subsidiary, Volition Veterinary Diagnostics Development LLC, in line with their corporate social responsibility strategy announces participation at the HOPE Animal-Assisted Crisis Response Dogs (HOPE AACR) Annual Conference in Virginia Beach.

HENDERSON, Nev. , Oct. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 11,550,000 shares of its common stock and warrants to purchase up to 11,550,000 shares of its common stock.

HENDERSON, Nev. , Oct. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it is proposing to offer and sell, in an underwritten public offering, shares of its common stock and accompanying common stock purchase warrants.

VolitionRx Limited - Special Call Company Participants Marielle Herzog Conference Call Participants Alexandra Byrne Eric Ariazi Presentation Alexandra Byrne Great. Good morning, everyone.

HENDERSON, Nev. , Oct. 2, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the sponsorship of a GenomeWeb webinar entitled "Beyond the Genome: Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery" on Wednesday, October 8 (details can be found below).

HENDERSON, Nev. , Sept. 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with Hologic Diagenode ("Hologic") for the co-marketing of Volition's Nu.Q® Discover service.